Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility study of intravesical mitomycin C chemoresection versus surgical management in recurrent low-risk non-muscle invasive bladder cancer
2013-005095-18Phase 2Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mitomycin c in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Complete response at 3 months. Status: unknown.
02
Drugs
mitomycin c
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2013-005095-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005095-18.